Showing 8211-8220 of 8908 results for "".
- SENTÉ Raises $5 million, Appoints New CEOhttps://practicaldermatology.com/news/sent-raises-5-million-appoints-new-ceo/2458713/There’s big news coming out of SENTÉ this week. Fresh of the announcement that they closed on a $5 million financing round, the company also appointed Laurent Combredet as President and Chief Executive Officer. Mr. Combredet was G
- Alastin SkinCare Appoints Lynn Salo to Board of Directorshttps://practicaldermatology.com/news/alastin-skincare-appoints-linda-salo-to-board-of-directors/2458719/Lynn Salo is now a member of ALASTIN™ Skincare, Inc.’s board of directors. Ms. Salo has 27 years of experience with Allergan in the U.S., Canada, and Europe, including her role as Vice President, Sales and Marketing for the Facial Aesthetic
- Survey: When it Come to Facial Aging Concerns, It's Like Mother, Like Daughterhttps://practicaldermatology.com/news/survey-when-it-come-to-facial-aging-concerns-its-like-mother-like-daughter/2458720/Galderma’s latest campaign Mom Genes™ aims to change the way moms and daughters talk about and approach facial aging. Fully 82 percent of moms hope facial aging is easier for their daughters, but more than half never talk about it togethe
- Bristol-Myers Squibb Foundation Awards 8 Grants to Make Skin and Lung Cancer Screening More Accessible in High-Risk U.S. Communitieshttps://practicaldermatology.com/news/bristol-myers-squibb-foundation-awards-8-grants-to-make-skin-and-lung-cancer-screening-more-accessible-in-high-risk-us-communities/2458721/Bristol-Myers Squibb Foundation awarded eight grants totaling nearly $11.5 million to help make skin and lung cancer screening programs, care and patient support more accessible to underserved populations. The grants we
- Meet the Neocutis' Family's Newest Add: Micro-Firm Neck and Décolleté Rejuvenating Complexhttps://practicaldermatology.com/news/meet-the-neocutis-familys-newest-add-micro-firm-neck-and-dcollet-rejuvenating-complex/2458723/Neocutis’ Micro-Firm Neck and Décolleté Rejuvenating Complex is slated to hit physician’s offices in March 2016. The cream, which will be the newest addition to the Neocutis family of anti-aging products, targets the delicate
- New Sunscreen Blocks UV Rays, Boosts Vitamin Dhttps://practicaldermatology.com/news/new-sunscreen-blocks-rays-boosts-vitamin-d/2458724/A new sunscreen may do more than block ultraviolet radiation, it may also allow the body to produce vitamin D. The sunscreen, Solar D, is currently available in Australia and will be available in the U.S. in summer 2016.The
- Dr. Andrew Krakowski Now CMO at DermOnehttps://practicaldermatology.com/news/andrew-krakowski-now-cmo-at-dermone/2458729/Andrew C. Krakowski, MD has joined DermOne, a network of comprehensive dermatology practices, as Chief Medical Officer. “The need for dermatology services has accelerated in recent years, due to an aging population, a growing demand for surgical and cosmetic procedures and a raised
- Rosacea, Glioma Linked: Are MMPs the Common Denominator?https://practicaldermatology.com/news/rosacea-glioma-linked-are-mmps-the-common-denominator/2458730/Rosacea may increase risk for glioma, according to a nationwide cohort study in Denmark. The findings, published online in JAMA Dermatology, suggest that an increased focus on neurologic sympt
- Vyome Biosciences: FDA Has Accepted IND for Investigational Acne Therapyhttps://practicaldermatology.com/news/vyome-biosciences-fda-has-accepted-ind-for-investigational-acne-therapy/2458728/The FDA has accepted from Vyome Biosciences an Investigational New Drug (IND) Application for the initiation of clinical studies for its lead program VB 1953, a topical therapeutic candidate for the treatment of moderate-to-severe acne. Vyome plans to start the Phase I clinical trials very soon.<
- Valeant: FDA Accepts BLA for Brodalumabhttps://practicaldermatology.com/news/valeant-fda-accepts-bla-for-brodalumab/2458726/The FDA has accepted for review the Biologics License Application (BLA) submitted by AstraZeneca in partnership with Valeant, for brodalumab injection, 210mg, a monoclonal antibody that targets the IL-17 receptor, in development for patients with moderate-to-severe plaque psoriasis. The FDA has a